期刊文献+

APOF和IGFALS基因在原发性肝癌组织中的表达及临床意义

Expression of APOF and IGFALS in primary hepatocellular carcinoma and its clinical significance
下载PDF
导出
摘要 目的探讨载脂蛋白F(apolipoprotein F,APOF)和人胰岛素样生长因子酸不稳定亚基(the insulin-like grouth factor binding protein acid labile subunit,IGFALS)在原发性肝癌组织中的表达及临床意义。方法选取2014年1月1日至2015年12月30日于广西医科大学附属肿瘤医院经手术切除及病理确诊为原发性肝癌88例,实时荧光定量PCR(qRT-PCR)法检测88例肝癌组织及其相应癌旁组织和6例正常肝组织中APOF基因和IGFALS基因mRNA的相对表达量,并分析两者表达与肝癌患者临床病理特征的关系。结果肝癌组织中APOF mRNA相对表达量低于癌旁组织和正常肝组织(0.156±0.019 vs 0.971±0.010,P<0.001;0.156±0.019 vs 81.140±0.092,P<0.001);肝癌组织中IGFALS mRNA相对表达量亦低于癌旁组织及正常肝组织(0.111±0.016 vs 1.090±0.054,P<0.001;0.111±0.016 vs 1.101±0.211,P<0.001)。APOF mRNA表达与门静脉侵犯相关(P=0.004);IGFALS mRNA表达与肿瘤分化程度、门静脉侵犯相关(P<0.05)。APOF mRNA表达水平与IGFALS mRNA表达水平呈正相关(r=0.332,P<0.01)。结论 APOF和IGFALS基因在肝癌组织中表达下调,二者表达呈正相关,且与门静脉侵犯有关,可能参与了肝癌的发生发展。 Objective To investigate the expression and clinical significance of apolipoprotein F (APOF) and human insulin-like growth factor acid labile subunit (IGFALS) in primary hepatocellular carcinoma. Methods Levels of APOF and IGFALS mRNA were examined in 88 cases of human liver cancer and adjacent tissues and 6 cases of normal liver tissue using quantitative real-time PCR. Relationships between mRNA levels and clinico-pathological factors were analyzed. Results Levels of APOF mRNA were significantly lower in hepatocellular carcinoma tissues (0.156 ± 0.019) than in paracancerous tissue (0.971±0.018) or normal liver tissue (1.140±0.092). Similarly, levels of IGFALS mRNA were significantly lower in hepatocellular carcinoma ( 0.111±0.016 ) than in adjacent tissues ( 1.090±0.054 ) or normal liver tissue (1.101±0.211, all P〈0.05 ). Expression of APOF was associated with portal vein invasion (P=0.004),while expression of IGFALS was associated with degree of differentiation and portal vein invasion (P〈0.05). Expression of APOF and IGFALS was lower among patients showing portal vein invasion than among those without portal vein invasion (P〈0.05). Expression of IGFALS was lower in the low- differentiation group than in the high-differentiation group(P〈0.05). Conclusions APOF and IGFALS are down-regulated in hepatocellular carcinoma tissues. Expression of the two genes positively correlates with each other, and their expression correlates with the extent of portal vein invasion and differentiation. These genes may be involved in the occurrence and development of hepatocellular carcinoma.
作者 何盼 范倪 陈思 唐艳萍 李科志 杨春 黄小青 曹骥 He Pan;Fan Ni;Chen Si;Tang Yanping;Li Kezhi;Yang Chun;Huang Xiaoqing;Cao Ji(Department of Research, Affiliated Tumor Hospital of Guangxi Medical University;Graduate Sehool of Guangxi Medical University;Key Laboratory of High-Incidence- Tumor Early Prevention and Treatment, Ministry of Education, Nanning 530021, China)
出处 《中国癌症防治杂志》 CAS 2018年第3期212-215,共4页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金 广西自然科学基金资助项目(2017GXNSFBA198003) 区域性高发肿瘤早期防治研究教育部重点实验室(GKE2017-ZZ01) 广西壮族自治区中青年教师基础能力提升项目(2017KY0102)
关键词 肝肿瘤 载脂蛋白F 胰岛素样生长因子酸不稳定亚基 实时荧光定量PCR 基因表达 Liver neoplasms APOF IGFALS Quantitative real-time PCR Gene expression
  • 相关文献

参考文献2

二级参考文献58

  • 1Schlupf J, Steinbeisser H. IGF antagonizes the Wnt/~-Catenin pathway and promotes differentiation of extra-embryonic endoderm. Differentiation, 2014, 87(5): 209-219.
  • 2Const~ncia M, Hemberger M, Hughes J, Dean W, Fergu- son-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, Reik W. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature, 2002, 417(6892): 945-948.
  • 3Wang YM, Nishida S, Sakata T, Elalieh HZ, Chang WH, Halloran BP, Dory SB, Bikle DD. Insulin-like growth factor-I is essential for embryonic bone development. Endocrinology, 2006, 147(10): 4753-4761.
  • 4Chen L, Jiang W, Huang JY, He BC, Zuo GW, Zhang WL, Luo Q, Shi Q, Zhang BQ, Wagner ER, Luo JY, Tang M, Wietholt C, Luo XJ, Bi Y, Su YX, Liu B, Kim SH, He C J, Hu YW, Shen JK, Rastegar F, Huang EY, Gao YH, Gao JL, Zhou JZ, Reid RR, Luu HH, Haydon RC, He TC, Deng ZL. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone for- mation. J Bone Miner Res, 2010, 25(11): 2447-2459.
  • 5Ibrahim YH, Yee D. Insulin-like growth factor-I and can- cer risk. Growth Horm IGF Res, 2004, 14(4): 261-269.
  • 6Ren J, Anversa P. The insulin-like growth factor I system: physiological and pathophysiological implication in car- diovascular diseases associated with metabolic syndrome. Biochem Pharmacol, 2015, 93(4): 409-417.
  • 7Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh), 1989, 121(6): 753-758.
  • 8Zapf J. Insulinlike growth factor binding proteins and tumor hypoglycemia. Trends Endocrinol Met, 1995, 6(2): 37-42.
  • 9Leong SR, Baxter RC, Camerato T, Dai J, Wood WI. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding pro- tein complex. Mol Endocrinol, 1992, 6(6): 870-876.
  • 10Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-bindingprotein complex: an important but forgotten component of the circulating IGF system. J Endocrinol, 2001, 170(1): 63-70.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部